Literature DB >> 15807861

Dichotomy of protective cellular immune responses to human visceral leishmaniasis.

E A G Khalil1, N B Ayed, A M Musa, M E Ibrahim, M M Mukhtar, E E Zijlstra, I M Elhassan, P G Smith, P M Kieny, H W Ghalib, F Zicker, F Modabber, A M Elhassan.   

Abstract

Healing/protective responses in human visceral leishmaniasis (VL) are associated with stimulation/production of Th1 cytokines, such as interferon IFN-gamma, and conversion in the leishmanin skin test (LST). Such responses were studied for 90 days in 44 adult healthy volunteers from VL non-endemic areas, with no past history of VL/cutaneous leishmaniasis (CL) and LST non-reactivity following injection with one of four doses of Alum-precipitated autoclaved Leishmania major (Alum/ALM) +/- bacille Calmette-Guerin (BCG), a VL candidate vaccine. The vaccine was well tolerated with minimal localized side-effects and without an increase in antileishmanial antibodies or interleukin (IL)-5. Five volunteers (5/44; 11.4%) had significant IFN-gamma production by peripheral blood mononuclear cells (PBMCs) in response to Leishmania antigens in their prevaccination samples (P = 0.001) but were LST non-reactive. On day 45, more than half the volunteers (26/44; 59.0%) had significantly high LST indurations (mean 9.2 +/- 2.7 mm) and high IFN-gamma levels (mean 1008 +/- 395; median 1247 pg/ml). Five volunteers had significant L. donovani antigen-induced IFN-gamma production (mean 873 +/- 290; median 902; P = 0.001), but were non-reactive in LST. An additional five volunteers (5/44; 11.4%) had low IFN-gamma levels (mean 110 +/- 124 pg/ml; median 80) and were non-reactive in LST (induration = 00 mm). The remaining eight volunteers had low IFN-gamma levels, but significant LST induration (mean 10 +/- 2.9 mm; median 11). By day 90 the majority of volunteers (27/44; 61.4%) had significant LST induration (mean 10.8 +/- 9.9 mm; P < 0.001), but low levels of L. donovani antigen-induced IFN-gamma (mean 66.0 +/- 62 pg/ml; P > 0.05). Eleven volunteers (11/44; 25%) had significantly high levels of IFN-gamma and LST induration, while five volunteers had low levels of IFN-gamma (<100 pg/ml) and no LST reactivity (00 mm). One volunteer was lost to follow-up. In conclusion, it is hypothesized that cellular immune responses to human VL are dichotomatous, and that IFN-gamma production and the LST response are not in a causal relationship. Following vaccination and probably cure of VL infection, the IFN-gamma response declines with time while the LST response persists. LST is a simple test that can be used to assess candidate vaccine efficacy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15807861      PMCID: PMC1809358          DOI: 10.1111/j.1365-2249.2005.02768.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  The effect of repeated leishmanin skin testing on the immune responses to Leishmania antigen in healthy volunteers.

Authors:  Iman Satti; Ahmed el Hassan; El Tahir A G Khalil; Hannah Akuffo
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 Sep-Oct       Impact factor: 2.184

2.  The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features.

Authors:  A M Musa; E A G Khalil; M A Raheem; E E Zijlstra; M E Ibrahim; I M Elhassan; M M Mukhtar; A M El Hassan
Journal:  Ann Trop Med Parasitol       Date:  2002-12

3.  IL-10 mediates susceptibility to Leishmania donovani infection.

Authors:  M L Murphy; U Wille; E N Villegas; C A Hunter; J P Farrell
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

4.  Leishmaniasis in Sudan. Visceral leishmaniasis.

Authors:  E E Zijlstra; A M el-Hassan
Journal:  Trans R Soc Trop Med Hyg       Date:  2001-04       Impact factor: 2.184

5.  Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers.

Authors:  I N Satti; H Y Osman; N S Daifalla; S A Younis; E A Khalil; E E Zijlstra; A M El Hassan; H W Ghalib
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

6.  Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

Authors:  I Sharifi; A R FeKri; M R Aflatonian; A Khamesipour; A Nadim; M R Mousavi; A Z Momeni; Y Dowlati; T Godal; F Zicker; P G Smith; F Modabber
Journal:  Lancet       Date:  1998-05-23       Impact factor: 79.321

7.  Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan.

Authors:  E A G Khalil; E E Zijlstra; P A Kager; A M El Hassan
Journal:  Trop Med Int Health       Date:  2002-01       Impact factor: 2.622

8.  The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC).

Authors:  S Gasim; A M Elhassan; A Kharazmi; E A Khalil; A Ismail; T G Theander
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

9.  Immunoblot analysis of the humoral immune response to Leishmania donovani polypeptides in cases of human visceral leishmaniasis: its usefulness in prognosis.

Authors:  Promod Kumar; Kalpana Pai; Kiran Tripathi; H P Pandey; Shyam Sundar
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

10.  Risk mapping of visceral leishmaniasis: the role of local variation in rainfall and altitude on the presence and incidence of kala-azar in eastern Sudan.

Authors:  Dia-Eldin A Elnaiem; Judith Schorscher; Anna Bendall; Valérie Obsomer; Maha E Osman; Abdelrafie M Mekkawi; Stephen J Connor; Richard W Ashford; Madeleine C Thomson
Journal:  Am J Trop Med Hyg       Date:  2003-01       Impact factor: 2.345

View more
  16 in total

1.  Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines.

Authors:  Mona E E Elfaki; Eltahir A G Khalil; Anne S De Groot; Ahmed M Musa; Andres Gutierrez; Brima M Younis; Kawthar A M Salih; Ahmed M El-Hassan
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

2.  Usefulness of the rK39-immunochromatographic test, direct agglutination test, and leishmanin skin test for detecting asymptomatic Leishmania infection in children in a new visceral leishmaniasis focus in Amhara State, Ethiopia.

Authors:  Endalamaw Gadisa; Estefanía Custodio; Carmen Cañavate; Luis Sordo; Zelalem Abebe; Javier Nieto; Carmen Chicharro; Abraham Aseffa; Lawrence Yamuah; Howard Engers; Javier Moreno; Israel Cruz
Journal:  Am J Trop Med Hyg       Date:  2012-05       Impact factor: 2.345

3.  Factors associated with Leishmania asymptomatic infection: results from a cross-sectional survey in highland northern Ethiopia.

Authors:  Estefanía Custodio; Endalamaw Gadisa; Luis Sordo; Israel Cruz; Javier Moreno; Javier Nieto; Carmen Chicharro; Abraham Aseffa; Zelalem Abraham; Tsegaye Hailu; Carmen Cañavate
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

4.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

5.  Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model.

Authors:  Rakhee Sachdeva; Akhil C Banerjea; Nancy Malla; Mohan Lal Dubey
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

Review 6.  A review of the leishmanin skin test: A neglected test for a neglected disease.

Authors:  Jessica Carstens-Kass; Kayla Paulini; Patrick Lypaczewski; Greg Matlashewski
Journal:  PLoS Negl Trop Dis       Date:  2021-07-22

7.  Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients.

Authors:  Eltahir Awad Gasim Khalil; Selma Abdelmoneim Khidir; Ahmed Mudawi Musa; Brema Younis Musa; Mona Elfaki Eltahir Elfaki; Abdelgadir Mohamed Yousif Elkadaru; Edward Zijlstra; Ahmed Mohamed El-Hassan
Journal:  J Trop Med       Date:  2013-03-24

8.  Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).

Authors:  Joshua Muli Mutiso; John Chege Macharia; Evans Taracha; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-01

9.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30

10.  Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis.

Authors:  Hashim Ghalib; Farrokh Modabber
Journal:  Kinetoplastid Biol Dis       Date:  2007-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.